Published in Curr Med Res Opin on January 01, 2006
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int (2015) 2.15
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int (2006) 1.29
Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med (2012) 1.17
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int (2010) 1.04
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int (2010) 0.97
Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab (2008) 0.90
An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporos Int (2013) 0.90
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int (2013) 0.87
PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int (2014) 0.87
Genotypes and clinical aspects associated with bone mineral density in Argentine postmenopausal women. J Bone Miner Metab (2008) 0.83
Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporos Int (2010) 0.80
Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Miner Bone Metab (2012) 0.80
The role of biochemical markers of bone turnover in osteoporosis management in clinical practice. Clin Biochem Rev (2006) 0.80
Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products. Nutr Res Rev (2014) 0.80
Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. J Bone Miner Metab (2009) 0.78
Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment. Clin Interv Aging (2008) 0.78
The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study. J Bone Miner Metab (2015) 0.77
A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int (2016) 0.77
The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos Int (2016) 0.76
Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation. Clin Interv Aging (2015) 0.75
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy. Curr Osteoporos Rep (2012) 0.75
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med (2003) 3.07
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc (2006) 1.96
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 1.82
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum (2007) 1.65
Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin (2012) 1.64
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause (2004) 1.57
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.54
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2007) 1.53
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Strategies for the prevention of hip fracture. Am J Med (2003) 1.50
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res (2007) 1.49
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone (2008) 1.48
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents. Arch Phys Med Rehabil (2005) 1.42
Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int (2005) 1.36
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab (2009) 1.35
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res (2005) 1.34
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab (2007) 1.32
Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am (2008) 1.27
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage (2004) 1.25
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 1.23
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res (2006) 1.20
Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab (2005) 1.19
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res (2003) 1.17
Quality of life in sarcopenia and frailty. Calcif Tissue Int (2013) 1.17
Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab (2004) 1.15
Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol (2011) 1.15
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res (2013) 1.14
The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab (2014) 1.14
Osteosarcoma and teriparatide? J Bone Miner Res (2007) 1.14
The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin (2005) 1.11
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther (2014) 1.11
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence (2013) 1.11
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother (2009) 1.10
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res (2010) 1.08
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging (2007) 1.07
New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage (2005) 1.06
D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res (2005) 1.06
Performance of osteoporosis risk assessment tools in postmenopausal women aged 45-64 years. Osteoporos Int (2004) 1.05
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord (2008) 1.04
Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol (2004) 1.03
Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res (2004) 1.03
Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin (2009) 1.02
The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol (2002) 1.02
Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int (2004) 1.01
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res (2009) 1.00
Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol (2005) 1.00
Development of a clinical assessment tool in identifying Asian men with low bone mineral density and comparison of its usefulness to quantitative bone ultrasound. Osteoporos Int (2004) 1.00
Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol (2006) 0.99
Prognostic utility of a semiquantitative spinal deformity index. Bone (2005) 0.99
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int (2005) 0.99
PINP as an aid for monitoring patients treated with teriparatide. Bone (2010) 0.98
Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res (2007) 0.98
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol (2008) 0.97
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin (2008) 0.96
Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics (2011) 0.96
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res (2004) 0.96
Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum (2013) 0.95
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy (2010) 0.95
Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int (2008) 0.94
Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res (2008) 0.94
Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int (2005) 0.94
The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health (2012) 0.93
Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. Aging Clin Exp Res (2004) 0.93
Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health (2011) 0.92
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcif Tissue Int (2010) 0.92
Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res (2008) 0.92
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin (2003) 0.92
Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone (2008) 0.91
Validity and reliability of the French version of the STarT Back screening tool for patients with low back pain. Spine (Phila Pa 1976) (2014) 0.91
Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab (2007) 0.91
Comparison of a simple clinical risk index and quantitative bone ultrasound for identifying women at increased risk of osteoporosis. Osteoporos Int (2003) 0.90
Treatment of postmenopausal osteoporosis. BMJ (2005) 0.90